WO2013149577A1 - 抗寄生虫药赛拉菌素的合成新工艺 - Google Patents
抗寄生虫药赛拉菌素的合成新工艺 Download PDFInfo
- Publication number
- WO2013149577A1 WO2013149577A1 PCT/CN2013/073604 CN2013073604W WO2013149577A1 WO 2013149577 A1 WO2013149577 A1 WO 2013149577A1 CN 2013073604 W CN2013073604 W CN 2013073604W WO 2013149577 A1 WO2013149577 A1 WO 2013149577A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- reaction
- iii
- group
- Prior art date
Links
- 0 CC([C@@]1O[C@@](CC2OC)OC(C)C2(O)O)[*-]=CCC1OC Chemical compound CC([C@@]1O[C@@](CC2OC)OC(C)C2(O)O)[*-]=CCC1OC 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Definitions
- Serramycin also known as sirolimus, serramycin, etc., chemical name (5Z, 25S) -25-cyclohexyl-4, -0-de(2,6-dideoxy-3-0- ⁇ Base - "-L-arabinopyranosyl” -5-deoxyoxy-25-de(1-mercaptopropyl)-22,23-dihydro-5-hydroxyimino avermectin Ala
- the "a” here refers to natural avermectin, wherein the 25-substituent is (S)-sec-butyl, and the "A” refers to the avermectin having a 5-substituted methoxy group.
- “1” refers to avermectin in which the double bond is in the 22-23 position, and its chemical structural formula is as follows:
- Serracin is a new strain of recombinant A. striata, which is a newer compound of avermectin. It is developed by Pfizer of the United States and is processed by Doramectin. A new generation of antiparasitic drugs obtained by chemically synthesizing structural modifications.
- Serramycin has a killing activity against in vivo (nematodes) and in vitro (arthropod) parasites, the same as other avermectins, which are caused by interfering with the chloride channel controlled by glutamate
- the worm body develops rapid, lethal and non-sacral neuromuscular paralysis.
- the drug is absorbed into the blood through the skin, and a part of the drug enters the digestive tract and blood through the mouth when the animal combs the coat.
- Pharmacokinetic studies have shown that serramycin in plasma after topical application shows sustained absorption.
- the test data indicates that the skin (especially the sebaceous gland) is the accumulation of serramycin, which ensures that the concentration of the drug that can kill the parasite on the endothelial hair is longer.
- the skin debris collected from the animal 30 days after the drug is still available. Kill the eggs and their larvae. Therefore, compared with the previous similar drugs, it has the disadvantages of poor performance, easy recurrence, inconvenient use, and poor pet tolerance. It can quickly, efficiently, conveniently and thoroughly kill the fleas that plague the pets and their owners. Heartworm, cockroach, cockroach, deafness and other internal and external parasites, and high safety, oral, injection have good results.
- the fourth step of the oximation reaction is carried out using hydroxylamine hydrochloride in anhydrous pyridine.
- serramycin was purified by silica gel column chromatography. This process is the basic patented process route of serramycin. The process route is long, the total yield is not high, and the industrial operation is troublesome.
- the hydrolysis reaction of the intermediate of the oxidation product with guanidine hydrochloride to produce 5-indole and the hydrolysis step to form a monosaccharide derivative is carried out as a single concurrent reaction, which greatly simplifies The procedure is followed, and the processing and separation steps can be reduced to improve the overall yield and quality of silamycin.
- active manganese dioxide is used as the oxidant, and the amount of the oxidant is large, and the post-treatment is difficult, and the industrial production brings great pressure to the environment.
- the third step of deuteration and de-sweating reaction the use of isopropanol/water system has a long reaction time, which is not conducive to improving efficiency in industrial production.
- the crude serramycin was prepared by deuteration and de-sweating reaction, and the optimal reaction conditions were explored by using the triethylamine method, the disodium hydrogen phosphate method, the reaction concentration method and the room temperature reaction method, respectively. 5% ⁇ The best conditions, the yield was 75.5%. Finally, crystallization of the cyanomycin (purity greater than 98.5%) was carried out twice with solvent A, and the total yield was 55%. This process is a relatively successful improvement on the cornerstone of the first two processes. The reaction route is short, the reaction conditions are relatively mild, and the total yield is 55%. However, the oxidant post-treatment used in the oxidation process of the second step produces a large amount of heavy metal-containing wastewater, which has a restrictive effect on industrial production.
- One of the objects of the present invention is to provide a novel key intermediate of silamycin
- a process for the preparation of a compound of the formula (?) which comprises: obtaining a compound of the formula (III) by oxidation of a compound of the formula (II):
- the solvent for the oxidation reaction is preferably dichlorosilane, trichlorodecane, toluene, acetone or tetrahydrofuran.
- the temperature of the oxidation reaction is preferably -78 to 30 °C.
- the above-mentioned oxidized anti-Chinese compound of formula (II) is obtained by adding a single bond of the double bond Wilkinson catalyst at the C-22, 23 position to the patent US6906184:
- the nucleophile for this reaction is preferably water.
- the reaction formula ( ⁇ ) compound preferably undergoes a nucleophilic addition reaction with a nucleophile such as water under acidic conditions to form an addition product ketone aqueous compound, a compound of the formula (IV), which is thermodynamically unstable. It is easy to lose water and re-convert to the original ketone. The addition is a reversible reaction, the balance is greatly biased and the reactants are in the process of separation. (IV) The compound is easily dehydrated and reconverted to the compound of formula (III), so it is difficult to separate it, and the compounds of formula (111) and (IV) have equivalent effects in the industrialization process of the process, and Need to be purified.
- a nucleophile such as water under acidic conditions
- the reaction is preferably carried out in a homogeneous system of a dC 3 alcohol and a homogeneous system of dioxane and water, dC alcohol and water.
- the temperature of the reaction is preferably 0-60 °C.
- the preferred route for the synthesis of silacin in the present invention is as follows (where route 1 is ruthenium sulfoxide as the oxidant; and route 2 is the Des s-Mart in reagent as the oxidant).
- the first step in the above reaction process preferably dissolves doramectin with toluene as a solvent
- the reaction temperature is 20-60 ° C, and with the action of Wilkinson catalyst tris(triphenylphosphine) ruthenium chloride (I), the reaction end point can be reached after 1-48 hours of reaction.
- the compound of formula (II) is isolated by filtration and removal of the solvent.
- dichloromethane is preferably used as a solvent, or an organic reagent such as chloroform, toluene, acetone or tetrahydrofuran may be added, and the sulfoxide is added with stirring, and the mixture is cooled to about 0 ° C while stirring, and then the addition of three is started.
- the mixture is cooled to -35-25
- the phenoxyphosphoryl dichloride is added dropwise, and the reaction is completed. The reaction is carried out at about 0.5 to 4 hours, and the reaction is terminated by adding 3 ⁇ 411 (0 3 aqueous solution.
- the third step is preferably carried out by reacting hydroxylamine hydrochloride with a compound of the formula ( ⁇ ) or the formula ( IV ) or a mixture thereof in a water bath at 0-60 ° C under the action of a sterol/dioxane/water mixed solvent. After 48 hours, the reaction end point can be reached, and then the mixture is extracted with dichloromethane and water, and the organic phase is collected and concentrated to obtain a crude serramycin.
- the advantages of the present invention over the prior art are:
- the present invention is an innovative process improvement based on the existing literature, which solves the deficiencies of the prior art process and provides a new method for preparing serramycin.
- the invention adopts doramectin as a starting material to obtain serramycin by three-step chemical synthesis reaction: the first hydrogenation reaction is still referred to the patent US6906184, and the double bond on the C-22, 23 position is in Wilkinson The catalyst is added as a single bond.
- the second oxidation reaction of the present invention uses disulfoxide, Des s-Mar t in reagent or the like as an oxidizing agent to oxidize the hydroxyl group at the C-5 position to a ketone, and at the same time, C-4, the hydroxyl group on the sugar is also oxidized to a bully base. A new intermediate is obtained to prepare silamycin, and the oxidizing agent is relatively easy to handle and has little contamination.
- the third step of deuteration, de-sweating is to deuterate the ketone at the C-5 position, while C-4, remove one molecule of sugar to obtain serramycin, in the process of the present invention, by changing the solvent type, thereby greatly Shorten the reaction time.
- the process of the invention is obviously optimized in the hydrogenation, oxidation and deuteration desaccharification processes in the prior literature, so that the total yield of the whole process is also obviously improved, the process time is shortened, the production efficiency is improved, and the pollution is correspondingly reduced.
- Example 1 The embodiments provided below have various aspects of the invention as described to illustrate the specific embodiments of the invention, but do not limit the invention.
- Example 1
- Oxidation reaction 100 g of the compound of the above formula (II) is dissolved in 1 L of dichloromethane, and 188 g of Des s-Mar t in reagent is added under vigorous stirring, and the reaction is kept at room temperature for 2 hours to reach the end of the reaction, and the diatomaceous earth is filtered to remove solids. Insoluble matter, the filtrate was washed with 500 mL of a NaHC0 3 /Na 2 S 2 3 3 (1:1) aqueous solution, and the aqueous phase was washed once again with 200 mL of dichloromethane. The organic phase was combined and washed once with water, and the organic phase was dried over anhydrous magnesium sulfate After 30 minutes, the solid was removed by filtration.
- the data of the R and 13 C R of the compound of the formula (III) are as follows:
- EtOAc EtOAc:EtOAc.
- Example 9 Deuteration and Deglycation Reaction 50 g of the compound of the formula (III) was dissolved in 400 ml of decyl alcohol and 400 ml of dioxane, and the temperature was lowered to an internal temperature of 10 ° C, and 50 g of an aqueous hydroxylamine hydrochloride solution dissolved in 50 mL of purified water was added thereto with stirring. . The internal temperature of the reaction solution was controlled to 10 ⁇ 2 ° C for 168 hours to reach the end of the reaction.
- the compound of the formula ( ⁇ ) was weighed in a single-necked flask, and the mixture was stirred for 2 hours at room temperature. 1% ⁇ The content of the compound of the formula (III) is 87.1%. The content of the compound of the formula (III) is 87.1%.
- Example 12 Deuteration and Desaccharification Reaction The hydroxyethylamine hydrochloride was added with 0.2 ml of purified water and 0.2 ml of purified hydrochloric acid. The reaction solution was heated to 40 ° C for 4 hours to reach the end of the reaction. The reaction mixture was quenched by the addition of 5 ml of water and 5 ml of dichloromethane.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13773160.0A EP2835376B1 (en) | 2012-04-03 | 2013-04-02 | New synthesis process of antiparasitic drug selamectin |
US14/389,802 US10053483B2 (en) | 2012-04-03 | 2013-04-02 | Synthesis process of antiparasitic drug selamectin |
JP2015503739A JP6084680B2 (ja) | 2012-04-03 | 2013-04-02 | 抗寄生虫薬セラメクチンの新規合成方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210102405.7A CN103360444B (zh) | 2012-04-03 | 2012-04-03 | 抗寄生虫药赛拉菌素的合成新工艺 |
CN201210102405.7 | 2012-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013149577A1 true WO2013149577A1 (zh) | 2013-10-10 |
Family
ID=49299998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/073604 WO2013149577A1 (zh) | 2012-04-03 | 2013-04-02 | 抗寄生虫药赛拉菌素的合成新工艺 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10053483B2 (zh) |
EP (1) | EP2835376B1 (zh) |
JP (1) | JP6084680B2 (zh) |
CN (1) | CN103360444B (zh) |
WO (1) | WO2013149577A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3150618A1 (en) | 2015-09-29 | 2017-04-05 | Virbac | Process for the preparation of selamectin |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018167271A1 (en) | 2017-03-17 | 2018-09-20 | Krka, D.D., Novo Mesto | Stable topical veterinary composition |
CN107118247B (zh) * | 2017-06-14 | 2019-07-26 | 博瑞生物医药(苏州)股份有限公司 | 塞拉菌素的制备方法 |
CN107021990B (zh) * | 2017-06-14 | 2019-07-12 | 博瑞生物医药(苏州)股份有限公司 | 高纯度塞拉菌素的制备方法 |
CN107188915B (zh) * | 2017-07-19 | 2019-08-02 | 苏州正永生物医药有限公司 | 一种塞拉菌素中间体的制备方法 |
CN109970822B (zh) * | 2017-12-27 | 2023-03-28 | 上海科胜药物研发有限公司 | 一种合成埃格列净中间体的制备方法 |
CN111116692A (zh) * | 2020-01-14 | 2020-05-08 | 北大方正集团有限公司 | 一种高纯度塞拉菌素的合成方法 |
CN114106071A (zh) * | 2021-11-11 | 2022-03-01 | 浙江荣耀生物科技股份有限公司 | 一种塞拉菌素的合成方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015944A1 (en) | 1993-01-18 | 1994-07-21 | Pfizer Limited | New antiparasitic agents related to the milbemycins and avermectins |
WO1999007721A1 (en) | 1997-08-05 | 1999-02-18 | Pfizer Limited | Improved process for antiparasitic agent |
US5981500A (en) | 1994-01-12 | 1999-11-09 | Pfizer Inc. | Antiparasitic agents related to the milbemycins and avermectins |
CN1724553A (zh) * | 2005-06-17 | 2006-01-25 | 华东师范大学 | 一种2’-脱氧-2’,2’-二氟-胞苷合成的方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4427663A (en) | 1982-03-16 | 1984-01-24 | Merck & Co., Inc. | 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof |
GB9201505D0 (en) * | 1992-01-24 | 1992-03-11 | Pfizer Ltd | Antiparasitic agents |
US5229416A (en) * | 1992-04-29 | 1993-07-20 | Merck & Co., Inc. | Avermectin difluoro derivatives |
GB9316129D0 (en) | 1993-08-04 | 1993-09-22 | Pfizer Ltd | Antiprasatic agents |
ES2387384T3 (es) | 1999-02-09 | 2012-09-21 | The Kitasato Institute | Derivados de avermectina |
GB0008353D0 (en) * | 2000-04-03 | 2000-05-24 | Pfizer Ltd | Method of treating a parasitic infection |
GB0302547D0 (en) | 2003-02-04 | 2003-03-12 | Syngenta Participations Ag | Avermectins and avermectin monosaccharide substituted in the 4'- and 4" position having pesticidal properties |
US7214791B2 (en) * | 2004-07-01 | 2007-05-08 | Shenzhen Hande Technology Co., Ltd. | Method for preparation of 2′-deoxy-2′, 2′-difluoro-β-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-β-d-glucose as raw material |
JP5595412B2 (ja) * | 2008-12-04 | 2014-09-24 | メリアル リミテッド | 二量体アベルメクチン及びミルベマイシン誘導体 |
-
2012
- 2012-04-03 CN CN201210102405.7A patent/CN103360444B/zh active Active
-
2013
- 2013-04-02 WO PCT/CN2013/073604 patent/WO2013149577A1/zh active Application Filing
- 2013-04-02 US US14/389,802 patent/US10053483B2/en active Active
- 2013-04-02 JP JP2015503739A patent/JP6084680B2/ja active Active
- 2013-04-02 EP EP13773160.0A patent/EP2835376B1/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015944A1 (en) | 1993-01-18 | 1994-07-21 | Pfizer Limited | New antiparasitic agents related to the milbemycins and avermectins |
EP0677054A1 (en) | 1993-01-18 | 1995-10-18 | Pfizer Inc. | New antiparasitic agents related to the milbemycins and avermectins |
US5981500A (en) | 1994-01-12 | 1999-11-09 | Pfizer Inc. | Antiparasitic agents related to the milbemycins and avermectins |
WO1999007721A1 (en) | 1997-08-05 | 1999-02-18 | Pfizer Limited | Improved process for antiparasitic agent |
EP1003764A1 (en) | 1997-08-05 | 2000-05-31 | Pfizer Limited | Improved process for antiparasitic agent |
CN1266437A (zh) * | 1997-08-05 | 2000-09-13 | 美国辉瑞有限公司 | 用于制备抗寄生物剂的改进方法 |
US6906184B1 (en) | 1997-08-05 | 2005-06-14 | Pifzer, Inc. | Process for antiparasitic agent |
CN1724553A (zh) * | 2005-06-17 | 2006-01-25 | 华东师范大学 | 一种2’-脱氧-2’,2’-二氟-胞苷合成的方法 |
Non-Patent Citations (1)
Title |
---|
SHIXIANG LV, MASTER'S THESIS OF NORTHEAST AGRICULTURAL UNIVERSITY, 2009 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3150618A1 (en) | 2015-09-29 | 2017-04-05 | Virbac | Process for the preparation of selamectin |
WO2017055502A1 (en) | 2015-09-29 | 2017-04-06 | Virbac | New synthesis process for the preparation of selamectin, and intermediates thereof |
Also Published As
Publication number | Publication date |
---|---|
US20150329581A1 (en) | 2015-11-19 |
JP2015512424A (ja) | 2015-04-27 |
JP6084680B2 (ja) | 2017-02-22 |
EP2835376B1 (en) | 2018-05-02 |
EP2835376A1 (en) | 2015-02-11 |
EP2835376A4 (en) | 2015-11-25 |
US10053483B2 (en) | 2018-08-21 |
CN103360444B (zh) | 2016-05-11 |
CN103360444A (zh) | 2013-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013149577A1 (zh) | 抗寄生虫药赛拉菌素的合成新工艺 | |
FR2951171A1 (fr) | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation | |
WO1999035155A1 (fr) | Nouveaux amides aromatiques, leur procede de preparation et leur application comme medicaments | |
JP2002544284A (ja) | C−2修飾エリスロマイシン誘導体 | |
KR20020008997A (ko) | 락톤계 당화합물에서의 키랄성 전환방법 | |
Karmakar et al. | Electrochemical and mechanochemical synthesis of dihydrofuro [3, 2-c] chromenones via intramolecular C sp3–H cross-dehydrogenative oxygenation within warfarin frameworks: an efficient and straightforward dual approach | |
CN105566266B (zh) | 15‑酮的制备方法 | |
JP3476476B2 (ja) | 抗寄生虫剤の改良方法 | |
FR2458556A1 (fr) | Derives de la paromomycine, procede pour les preparer et leur usage comme medicament | |
CN102775450A (zh) | 一种1,6-脱水-2-叠氮-2-脱氧-β-D-吡喃葡萄糖的制备方法 | |
CN106674142A (zh) | 一种帕瑞昔布钠及其中间体的制备方法 | |
CA2258152C (fr) | Nouveaux derives aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments | |
KR20190056863A (ko) | 신규한 셀라멕틴 중간체, 이의 제조방법 및 이를 이용한 셀라멕틴의 제조방법 | |
WO2012062109A1 (zh) | 阿利克仑的药物中间体的制备方法 | |
CN108440395A (zh) | 一种米力农杂质的制备方法 | |
JP2003533444A (ja) | 6−o−プロパルギルエリスロマイシン誘導体の調製法 | |
EP0656364A1 (fr) | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments | |
RU2817042C1 (ru) | Способ синтеза промежуточного соединения для получения ингибитора натрий-зависимого котранспортера глюкозы (sglt) | |
CN104140376B (zh) | 一种合成5-氨基乙酰丙酸的方法 | |
CN106554381A (zh) | 酮内酯类抗生素中间体及其制备方法和应用 | |
RU2339623C1 (ru) | Способ получения нитропроизводных 2-галоген-9,10-дигидро-9-акридинонов из 5-галоген-3-арил-2,1-бензизоксазолов | |
JPS6391396A (ja) | エリスロマイシンa誘導体の製造方法 | |
CN112300226A (zh) | 一种制备β-四乙酰-L-核糖的方法 | |
SU578007A3 (ru) | Способ получени производных просцилларидина | |
CN108299252A (zh) | 一种去甲肾上腺素磺酸类代谢物的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13773160 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14389802 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015503739 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013773160 Country of ref document: EP |